1.Spironolactone Attenuates Methylglyoxal-induced Cellular Dysfunction in MC3T3-E1 Osteoblastic Cells
So Young PARK ; Kwang Sik SUH ; Woon-Won JUNG ; Sang Ouk CHIN
Journal of Korean Medical Science 2021;36(38):e265-
		                        		
		                        			Background:
		                        			Methylglyoxal (MG) is associated with the pathogenesis of age- and diabetes-related complications. Spironolactone is a competitive antagonist of aldosterone that is widely employed in the treatment of hypertension and heart failure. This study examined the effects of spironolactone on MG-induced cellular dysfunction in MC3T3-E1 osteoblastic cells. 
		                        		
		                        			Methods:
		                        			MC3T3-E1 cells were treated with spironolactone in the presence of MG. The mitochondrial function, bone formation activity, oxidative damage, inflammatory cytokines, glyoxalase I activity, and glutathione (GSH) were measured. 
		                        		
		                        			Results:
		                        			Pretreatment of MC3T3-E1 osteoblastic cells with spironolactone prevented MG-induced cell death, and improved bone formation activity. Spironolactone reduced MG-induced endoplasmic reticulum stress, production of intracellular reactive oxygen species, mitochondrial superoxides, cardiolipin peroxidation, and inflammatory cytokines. Pretreatment with spironolactone also increased the level of reduced GSH and the activity of glyoxalase I. MG induced mitochondrial dysfunction, but markers of mitochondrial biogenesis such as mitochondrial membrane potential, adenosine triphosphate, proliferator-activated receptor gamma coactivator 1α, and nitric oxide were significantly improved by treatment of spironolactone. 
		                        		
		                        			Conclusion
		                        			Spironolactone could prevent MG-induced cytotoxicity in MC3T3-E1 osteoblastic cells by reduction of oxidative stress. The oxidative stress reduction was explained by spironolactone's inhibition of advanced glycation end-product formation, restoring mitochondrial dysfunction, and anti-inflammatory effect.
		                        		
		                        		
		                        		
		                        	
2.Spironolactone Attenuates Methylglyoxal-induced Cellular Dysfunction in MC3T3-E1 Osteoblastic Cells
So Young PARK ; Kwang Sik SUH ; Woon-Won JUNG ; Sang Ouk CHIN
Journal of Korean Medical Science 2021;36(38):e265-
		                        		
		                        			Background:
		                        			Methylglyoxal (MG) is associated with the pathogenesis of age- and diabetes-related complications. Spironolactone is a competitive antagonist of aldosterone that is widely employed in the treatment of hypertension and heart failure. This study examined the effects of spironolactone on MG-induced cellular dysfunction in MC3T3-E1 osteoblastic cells. 
		                        		
		                        			Methods:
		                        			MC3T3-E1 cells were treated with spironolactone in the presence of MG. The mitochondrial function, bone formation activity, oxidative damage, inflammatory cytokines, glyoxalase I activity, and glutathione (GSH) were measured. 
		                        		
		                        			Results:
		                        			Pretreatment of MC3T3-E1 osteoblastic cells with spironolactone prevented MG-induced cell death, and improved bone formation activity. Spironolactone reduced MG-induced endoplasmic reticulum stress, production of intracellular reactive oxygen species, mitochondrial superoxides, cardiolipin peroxidation, and inflammatory cytokines. Pretreatment with spironolactone also increased the level of reduced GSH and the activity of glyoxalase I. MG induced mitochondrial dysfunction, but markers of mitochondrial biogenesis such as mitochondrial membrane potential, adenosine triphosphate, proliferator-activated receptor gamma coactivator 1α, and nitric oxide were significantly improved by treatment of spironolactone. 
		                        		
		                        			Conclusion
		                        			Spironolactone could prevent MG-induced cytotoxicity in MC3T3-E1 osteoblastic cells by reduction of oxidative stress. The oxidative stress reduction was explained by spironolactone's inhibition of advanced glycation end-product formation, restoring mitochondrial dysfunction, and anti-inflammatory effect.
		                        		
		                        		
		                        		
		                        	
3.2020 Clinical Practice Guideline for Percutaneous Transthoracic Needle Biopsy of Pulmonary Lesions: A Consensus Statement and Recommendations of the Korean Society of Thoracic Radiology
Soon Ho YOON ; Sang Min LEE ; Chul Hwan PARK ; Jong Hyuk LEE ; Hyungjin KIM ; Kum Ju CHAE ; Kwang Nam JIN ; Kyung Hee LEE ; Jung Im KIM ; Jung Hee HONG ; Eui Jin HWANG ; Heekyung KIM ; Young Joo SUH ; Samina PARK ; Young Sik PARK ; Dong-Wan KIM ; Miyoung CHOI ; Chang Min PARK
Korean Journal of Radiology 2021;22(2):263-280
		                        		
		                        			
		                        			 Percutaneous transthoracic needle biopsy (PTNB) is one of the essential diagnostic procedures for pulmonary lesions. Its role is increasing in the era of CT screening for lung cancer and precision medicine. The Korean Society of Thoracic Radiology developed the first evidence-based clinical guideline for PTNB in Korea by adapting pre-existing guidelines. The guideline provides 39 recommendations for the following four main domains of 12 key questions: the indications for PTNB, pre-procedural evaluation, procedural technique of PTNB and its accuracy, and management of post-biopsy complications. We hope that these recommendations can improve the diagnostic accuracy and safety of PTNB in clinical practice and promote standardization of the procedure nationwide. 
		                        		
		                        		
		                        		
		                        	
4.Tetrabromobisphenol A Promotes the Osteoclastogenesis of RAW264.7 Cells Induced by Receptor Activator of NF-kappa B Ligand In Vitro
So Young PARK ; Eun Mi CHOI ; Kwang Sik SUH ; Hyun Sook KIM ; Sang Ouk CHIN ; Sang Youl RHEE ; Deog Yoon KIM ; Seungjoon OH ; Suk CHON
Journal of Korean Medical Science 2019;34(41):e267-
		                        		
		                        			
		                        			BACKGROUND: Tetrabromobisphenol A (TBBPA), one of the most widely used brominated flame-retardants, is a representative persistent organic pollutants group. Studies on TBBPA toxicity have been conducted using various target cells; however, few studies have investigated TBBPA toxicity in bone cells. Therefore, this study investigated the in vitro effects of TBBPA on osteoclasts, a cell type involved in bone metabolism. METHODS: RAW264.7 cells were cultured in medium containing 50 ng/mL receptor activator of nuclear factor kappa B ligand (RANKL) and varying concentrations of TBBPA. To evaluate the effects of TBBPA on the differentiation and function of osteoclasts, osteoclast-specific gene expression, tartrate-resistant acid phosphatase (TRAP) activity, bone resorbing activity, mitochondrial membrane potential (MMP) and mitochondrial superoxide were measured. RESULTS: The presence of 20 μM TBBPA significantly increased TRAP activity in RANKL-stimulated RAW264.7 cells, the bone resorbing activity of osteoclasts, and the gene expression of Akt2, nuclear factor of activated T-cells cytoplasmic 1, and chloride channel voltage-sensitive 7. However, TBBPA treatment caused no change in the expression of carbonic anhydrase II, cathepsin K, osteopetrosis-associated transmembrane protein 1, Src, extracellular signal-related kinase, GAB2, c-Fos, or matrix metalloproteinase 9. Furthermore, 20 μM TBBPA caused a significant decrease in MMP and a significant increase in mitochondrial superoxide production. CONCLUSION: This study suggests that TBBPA promotes osteoclast differentiation and activity. The mechanism of TBBPA-stimulated osteoclastogenesis might include increased expression of several genes involved in osteoclast differentiation and reactive oxygen species production.
		                        		
		                        		
		                        		
		                        			Acid Phosphatase
		                        			;
		                        		
		                        			Carbonic Anhydrase II
		                        			;
		                        		
		                        			Cathepsin K
		                        			;
		                        		
		                        			Chloride Channels
		                        			;
		                        		
		                        			Cytoplasm
		                        			;
		                        		
		                        			Gene Expression
		                        			;
		                        		
		                        			In Vitro Techniques
		                        			;
		                        		
		                        			Matrix Metalloproteinase 9
		                        			;
		                        		
		                        			Membrane Potential, Mitochondrial
		                        			;
		                        		
		                        			Metabolism
		                        			;
		                        		
		                        			Osteoclasts
		                        			;
		                        		
		                        			Phosphotransferases
		                        			;
		                        		
		                        			RANK Ligand
		                        			;
		                        		
		                        			Reactive Oxygen Species
		                        			;
		                        		
		                        			Receptor Activator of Nuclear Factor-kappa B
		                        			;
		                        		
		                        			Superoxides
		                        			;
		                        		
		                        			T-Lymphocytes
		                        			
		                        		
		                        	
5.2017 Thyroid Radiofrequency Ablation Guideline: Korean Society of Thyroid Radiology.
Ji hoon KIM ; Jung Hwan BAEK ; Hyun Kyung LIM ; Hye Shin AHN ; Seon Mi BAEK ; Yoon Jung CHOI ; Young Jun CHOI ; Sae Rom CHUNG ; Eun Ju HA ; Soo Yeon HAHN ; So Lyung JUNG ; Dae Sik KIM ; Soo Jin KIM ; Yeo Koon KIM ; Chang Yoon LEE ; Jeong Hyun LEE ; Kwang Hwi LEE ; Young Hen LEE ; Jeong Seon PARK ; Hyesun PARK ; Jung Hee SHIN ; Chong Hyun SUH ; Jin Yong SUNG ; Jung Suk SIM ; Inyoung YOUN ; Miyoung CHOI ; Dong Gyu NA
Korean Journal of Radiology 2018;19(4):632-655
		                        		
		                        			
		                        			Thermal ablation using radiofrequency is a new, minimally invasive modality employed as an alternative to surgery in patients with benign thyroid nodules and recurrent thyroid cancers. The Task Force Committee of the Korean Society of Thyroid Radiology (KSThR) developed recommendations for the optimal use of radiofrequency ablation for thyroid tumors in 2012. As new meaningful evidences have accumulated, KSThR decided to revise the guidelines. The revised guideline is based on a comprehensive analysis of the current literature and expert consensus.
		                        		
		                        		
		                        		
		                        			Advisory Committees
		                        			;
		                        		
		                        			Catheter Ablation*
		                        			;
		                        		
		                        			Consensus
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Thyroid Gland*
		                        			;
		                        		
		                        			Thyroid Neoplasms
		                        			;
		                        		
		                        			Thyroid Nodule
		                        			;
		                        		
		                        			Ultrasonography
		                        			
		                        		
		                        	
6.SEALONE (Safety and Efficacy of Coronary Computed Tomography Angiography with Low Dose in Patients Visiting Emergency Room) trial: study protocol for a randomized controlled trial.
Joonghee KIM ; Joon Won KANG ; Kyuseok KIM ; Sang Il CHOI ; Eun Ju CHUN ; Yeo Goon KIM ; Won Young KIM ; Dong Woo SEO ; Jonghwan SHIN ; Huijai LEE ; Kwang Nam JIN ; Soyeon AHN ; Seung Sik HWANG ; Kwang Pyo KIM ; Ru Bi JEONG ; Sang Ook HA ; Byungho CHOI ; Chang Hwan YOON ; Jung Won SUH ; Hack Lyoung KIM ; Ju Kyoung KIM ; Sujin JANG ; Ji Seon SEO
Clinical and Experimental Emergency Medicine 2017;4(4):208-213
		                        		
		                        			
		                        			OBJECTIVE: Chest pain is one of the most common complaints in the emergency department (ED). Cardiac computed tomography angiography (CCTA) is a frequently used tool for the early triage of patients with low- to intermediate-risk acute chest pain. We present a study protocol for a multicenter prospective randomized controlled clinical trial testing the hypothesis that a low-dose CCTA protocol using prospective electrocardiogram (ECG)-triggering and limited-scan range can provide sufficient diagnostic safety for early triage of patients with acute chest pain. METHODS: The trial will include 681 younger adult (aged 20 to 55) patients visiting EDs of three academic hospitals for acute chest pain or equivalent symptoms who require further evaluation to rule out acute coronary syndrome. Participants will be randomly allocated to either low-dose or conventional CCTA protocol at a 2:1 ratio. The low-dose group will undergo CCTA with prospective ECG-triggering and restricted scan range from sub-carina to heart base. The conventional protocol group will undergo CCTA with retrospective ECG-gating covering the entire chest. Patient disposition is determined based on computed tomography findings and clinical progression and all patients are followed for a month. The primary objective is to prove that the chance of experiencing any hard event within 30 days after a negative low-dose CCTA is less than 1%. The secondary objectives are comparisons of the amount of radiation exposure, ED length of stay and overall cost. RESULTS AND CONCLUSION: Our low-dose protocol is readily applicable to current multi-detector computed tomography devices. If this study proves its safety and efficacy, dose-reduction without purchasing of expensive newer devices would be possible.
		                        		
		                        		
		                        		
		                        			Acute Coronary Syndrome
		                        			;
		                        		
		                        			Adult
		                        			;
		                        		
		                        			Angiography*
		                        			;
		                        		
		                        			Chest Pain
		                        			;
		                        		
		                        			Coronary Angiography
		                        			;
		                        		
		                        			Electrocardiography
		                        			;
		                        		
		                        			Emergencies*
		                        			;
		                        		
		                        			Emergency Service, Hospital
		                        			;
		                        		
		                        			Heart
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Length of Stay
		                        			;
		                        		
		                        			Prospective Studies
		                        			;
		                        		
		                        			Radiation Exposure
		                        			;
		                        		
		                        			Retrospective Studies
		                        			;
		                        		
		                        			Thorax
		                        			;
		                        		
		                        			Triage
		                        			
		                        		
		                        	
7.Living Donor Liver Transplantation for an Infant with Osteogenesis Imperfecta and Intrahepatic Cholestasis: Report of a Case.
Youngrok CHOI ; Nam Joon YI ; Jae Sung KO ; Jung Min KO ; Ung Sik JIN ; Hee Soo KIM ; Kook Hyun LEE ; Tae Joon CHO ; Suk Won SUH ; Tae YOO ; Kwang Woong LEE ; Kyung Suk SUH
Journal of Korean Medical Science 2014;29(3):441-444
		                        		
		                        			
		                        			Osteogenesis imperfecta (OI) is a group of genetic disorders characterized by bone fragility and connective tissue manifestations. We report a successful liver transplantation (LT) in an 8-month-old boy with OI and cholestatic biliary cirrhosis. After 4 cycles of intravenous pamidronate, LT was performed under intravenous anesthesia using a left lateral section from his mother without mechanical retractors. The operation time was 420 min and estimated blood loss was 520 mL requiring one unit of RBC transfusion. He was discharged without surgical complications. Therefore, LT should be considered for patients with end stage liver disease and OI under organic multidisciplinary cooperation.
		                        		
		                        		
		                        		
		                        			Bone Density
		                        			;
		                        		
		                        			Bone Density Conservation Agents/therapeutic use
		                        			;
		                        		
		                        			Cholestasis, Intrahepatic/*diagnosis
		                        			;
		                        		
		                        			Diphosphonates/therapeutic use
		                        			;
		                        		
		                        			Fractures, Bone/drug therapy/etiology/radiography
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Infant
		                        			;
		                        		
		                        			*Liver Transplantation
		                        			;
		                        		
		                        			Living Donors
		                        			;
		                        		
		                        			Male
		                        			;
		                        		
		                        			Osteogenesis Imperfecta/complications/*surgery
		                        			
		                        		
		                        	
8.High effectiveness of peginterferon alfa-2a plus ribavirin therapy in Korean patients with chronic hepatitis C in clinical practice.
Nae Yun HEO ; Young Suk LIM ; Han Chu LEE ; Yung Sang LEE ; Kang Mo KIM ; Kwan Soo BYUN ; Kwang Hyub HAN ; Kwan Sik LEE ; Seung Woon PAIK ; Seung Kew YOON ; Dong Jin SUH
Clinical and Molecular Hepatology 2013;19(1):60-69
		                        		
		                        			
		                        			BACKGROUND/AIMS: Identifying the impact of a patient's ethnicity on treatment responses in clinical practice may assist in providing individualized treatment regimens for chronic hepatitis C (CHC). The effectiveness of standard peginterferon plus ribavirin therapy and the need for triple combination therapy with protease inhibitors in Koreans remain matters of debate. These issues were investigated in the present study. METHODS: The clinical data of 272 treatment-naive Korean CHC patients who were treated in a community-based clinical trial (Clinical Trial group; n=51) and in clinical practice (Cohort group; n=221), were analyzed and compared. All were treated with standard protocols of peginterferon alfa-2a plus ribavirin therapy. RESULTS: For patients with hepatitis C virus (HCV) genotype 1, the sustained virological response (SVR) rates in the Clinical Trial and Cohort groups were 81% (21/26) and 55% (58/106), respectively, by intention-to-treat (ITT) analysis (P=0.02), and 100% (13/13) and 80% (32/40), respectively, in treatment-adherent patients (P=0.18). For patients with HCV genotype 2, the SVR rates in these two groups were 96% (24/25) and 88% (101/115), respectively, by ITT analysis (P=0.31). Adherence and treatment duration were independent predictors of SVR for genotypes 1 and 2, respectively (P<0.01 for each). Korean patients with CHC achieved high SVR rates with peginterferon alfa-2a plus ribavirin in both the clinical trial and clinical practice settings. CONCLUSIONS: Measures to raise adherence to standard therapy in clinical practice may improve the SVR rates in these patients as effectively as adding protease inhibitors, thus obviating the need for the latter.
		                        		
		                        		
		                        		
		                        			Adolescent
		                        			;
		                        		
		                        			Adult
		                        			;
		                        		
		                        			Aged
		                        			;
		                        		
		                        			Antiviral Agents/*therapeutic use
		                        			;
		                        		
		                        			Asian Continental Ancestry Group
		                        			;
		                        		
		                        			Cohort Studies
		                        			;
		                        		
		                        			Drug Therapy, Combination
		                        			;
		                        		
		                        			Female
		                        			;
		                        		
		                        			Genotype
		                        			;
		                        		
		                        			Hepacivirus/genetics
		                        			;
		                        		
		                        			Hepatitis C, Chronic/*drug therapy
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Interferon-alpha/*therapeutic use
		                        			;
		                        		
		                        			Male
		                        			;
		                        		
		                        			Middle Aged
		                        			;
		                        		
		                        			Odds Ratio
		                        			;
		                        		
		                        			Polyethylene Glycols/*therapeutic use
		                        			;
		                        		
		                        			Predictive Value of Tests
		                        			;
		                        		
		                        			RNA, Viral/genetics
		                        			;
		                        		
		                        			Recombinant Proteins/therapeutic use
		                        			;
		                        		
		                        			Republic of Korea
		                        			;
		                        		
		                        			Ribavirin/*therapeutic use
		                        			;
		                        		
		                        			Treatment Outcome
		                        			;
		                        		
		                        			Young Adult
		                        			
		                        		
		                        	
9.Isolation of Density Enrichment Fraction of Adipose-Derived Stem Cells from Stromal Vascular Fraction by Gradient Centrifugation Method.
Min Kyung KIM ; Yong Soon PARK ; Hee Soon PARK ; Jung Mook CHOI ; Won Jun KIM ; Se Eun PARK ; Eun Jung RHEE ; Cheol Young PARK ; Won Young LEE ; Ki Won OH ; Sung Woo PARK ; Sun Woo KIM ; Kwang Sik SUH ; Jeong Taek WOO
Endocrinology and Metabolism 2010;25(2):103-109
		                        		
		                        			
		                        			BACKGROUND: Adipose tissues include multipotent cells, the same as bone marrow-derived mesenchymal stem cells. The stromal vascular fractions (SVFs) from adipose tissues represent a heterogeneous cell population. The purpose of this study was to isolate and purify adipose-derived stem cells (ASCs) in SVFs by the density gradient method. METHODS: SVFs were extracted from the subcutaneous, epididymal, mesenteric and retroperitoneal adipose tissue of 8 weeks old male Sprague-Dawley rats (n = 15) and these were separated into 4 layers according to a Nycodenz gradient (Fx-1: < 11%, Fx-2: 11-13%, Fx-3: 13-19% and Fx-4: 19-30%). The post-confluent SVFs were cultured in adipogenic medium for 2 days, in insulin medium for 2 days and in 10% fetal bovine serum medium for 5 days. To observe lipid droplets in SVFs, we performed Oil Red O staining. RESLTS: The SVFs' cellular fractions (Fx-1, Fx-2, Fx-3 and Fx-4) were isolated by density gradient centrifugation from the adipose tissues of rats. The SVFs extracted to fraction 3 (Fx-3) had the most abundant cells compared to that of the other fractions. However fraction 1 (Fx-1) or 2 (Fx-2) had a superior ability to make lipid droplets. The adipogenic differentiation of Fx-1 or 2 was higher than that of the unfractionated cells. The SVFs extracted from retroperitoneal adipose tissue had the highest efficiency for adipogenic differentiation, whereas the SVFs from mesenteric adipose tissue did not differentiate. CONCLUSION: This density gradient fractionated method leads to efficient isolation and purification of cells with the characteristics of ASCs.
		                        		
		                        		
		                        		
		                        			Adipose Tissue
		                        			;
		                        		
		                        			Animals
		                        			;
		                        		
		                        			Azo Compounds
		                        			;
		                        		
		                        			Centrifugation
		                        			;
		                        		
		                        			Centrifugation, Density Gradient
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Insulin
		                        			;
		                        		
		                        			Intra-Abdominal Fat
		                        			;
		                        		
		                        			Iohexol
		                        			;
		                        		
		                        			Male
		                        			;
		                        		
		                        			Mesenchymal Stromal Cells
		                        			;
		                        		
		                        			Rats
		                        			;
		                        		
		                        			Rats, Sprague-Dawley
		                        			;
		                        		
		                        			Stem Cells
		                        			
		                        		
		                        	
10.Henoch-Schonlein Purpura and Peroneal Nerve Palsy after Hemorrhagic Fever with Renal Syndrome.
Eui Sik KIM ; Won Ik JANG ; Ji Yoon JUNG ; Sarah CHUNG ; Dae Eun CHOI ; Bum Jin IM ; Ki Ryang NA ; Kang Wook LEE ; Kwang Sun SUH ; Young Tai SHIN
Korean Journal of Nephrology 2009;28(6):634-638
		                        		
		                        			
		                        			In the course of hemorrhagic fever with renal syndrome (HFRS), mild neurological symptoms such as headache, vertigo and nausea are common. Peripheral neuropathy in HFRS is very rare. Henoch- Sch?nlein purpura (HSP) is an immunologically medicated systemic vasculitis of small blood vessels affecting the skin, gastrointestinal tract, joints and kidneys, predominantly. Neurological complications in HSP include headache, focal cerebral deficit, coma, convulsion, subarachnoid hemorrhage and chorea. Peripheral neuropathy is also very rare. However there was no case report about HSP and peroneal nerve palsy after HFRS. With a brief review of the literature, we report a case of HSP and peroneal nerve palsy following HFRS.
		                        		
		                        		
		                        		
		                        			Blood Vessels
		                        			;
		                        		
		                        			Chorea
		                        			;
		                        		
		                        			Coma
		                        			;
		                        		
		                        			Gastrointestinal Tract
		                        			;
		                        		
		                        			Headache
		                        			;
		                        		
		                        			Hemorrhagic Fever with Renal Syndrome
		                        			;
		                        		
		                        			Joints
		                        			;
		                        		
		                        			Kidney
		                        			;
		                        		
		                        			Nausea
		                        			;
		                        		
		                        			Paralysis
		                        			;
		                        		
		                        			Peripheral Nervous System Diseases
		                        			;
		                        		
		                        			Peroneal Nerve
		                        			;
		                        		
		                        			Purpura
		                        			;
		                        		
		                        			Purpura, Schoenlein-Henoch
		                        			;
		                        		
		                        			Seizures
		                        			;
		                        		
		                        			Skin
		                        			;
		                        		
		                        			Subarachnoid Hemorrhage
		                        			;
		                        		
		                        			Systemic Vasculitis
		                        			;
		                        		
		                        			Vertigo
		                        			
		                        		
		                        	
            
Result Analysis
Print
Save
E-mail